Format:
Online-Ressource (XVIII, 832 p. 103 illus., 68 illus. in color, online resource)
ISBN:
9788132211846
Series Statement:
SpringerLink
Content:
“Omics for Personalized Medicine†will give to its prospective readers the insight of both the current developments and the future potential of personalized medicine. The book brings into light how the pharmacogenomics and omics technologies are bringing a revolution in transforming the medicine and the health care sector for the better. Students of biomedical research and medicine along with medical professionals will benefit tremendously from the book by gaining from the diverse fields of knowledge of new age personalized medicine presented in the highly detailed chapters of the book. Th
Note:
Description based upon print version of record
,
Foreword; Preface; About the Book; Contents; Section I: General Aspects of Pharmacogenomics; 1: Pharmacogenomics, Pharmacoproteomics, and Pharmacometabolomics and Personalized Medicine: An Overview; 1 Personalized Medicine; 1.1 Basic Concepts; 1.2 Benefits and Challenges; 2 Pharmacogenomics and Personalized Medicine; 2.1 Basic Concepts; 2.2 Tools and Technologies; 2.3 Applications in Medicine; 2.4 Challenges; 3 Pharmacoproteomics; 3.1 Basic Concepts; 3.2 Tools and Technologies; 3.3 Applications; 3.4 Challenges; 4 Pharmacometabolomics; 4.1 Basic Concepts; 4.2 Tools and Technologies
,
4.3 Applications4.4 Challenges; 5 Future Perspectives; References; 2: Personalized Genome, Current Status, and the Future of Pharmacogenomics; 1 Introduction; 2 Adverse Drug Reaction and the Need for Personalized Medicine; 3 Pharmacology; 4 Genetics; 5 Human Genome Project (HGP); 6 HapMap; 7 SNPs; 8 Genome-Wide Association Studies (GWAS) Data in Pharmacogenomics; 9 Clinical Use of Genomes in Pharmacogenomics; 10 Benefits of Pharmacogenomics; 10.1 Development of More Safe and Potent Medicines; 10.2 Selection of the Drug Based on Pharmacogenomic Informations
,
10.3 Determination of Accurate Drug Dosage and Development of Modern Screening Protocols10.4 Evolution of Drug Development and Approval and Reduced Cost of Health Care; 11 Pharmacogenomics Today; 12 Future Pharmacogenomic Strategies in the Management of Brain Tumors; 12.1 SNPs and LOH Status in Human Brain Tumors; 12.2 Posttranslational Modification of Proteins in Human Brain Tumors; 12.3 Tumor Heterogeneity and Pharmacogenomics; 12.4 Duplex Sequencing; 13 Ethical Issues; 13.1 Individuals' Affordability and Patient Benefits of Pharmacogenomics
,
13.2 Benefits to the Patients Involved in Initial Drug Trials13.3 Ethical Use of Individualized Medicine; 14 Pharmacogenomics and Protection of Individual Rights; 15 What Is Health Insurance Portability and Accountability Act (HIPPA), USA; 16 Risk of Pharmacogenomics; 16.1 Risk of Psychological Harm; 16.2 Insufficient Drug Alternatives for a Selected Group of Patients; 16.3 Obstructions in the Development of Pharmacogenomics-Based Patient Management; 17 Conclusion; R eferences; Websites on SNPs, SNPs in Cancer, GWAS
,
3: Next-Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine1 Introduction; 1.1 Personalized Medicine; 1.2 Pharmacogenomics; 1.3 Biomarkers in Pharmacogenomics; 1.3.1 Genetic Biomarkers; 1.3.2 Epigenetic Biomarkers; 1.3.3 Transcriptomic Biomarkers; 1.4 Technologies for Pharmacogenomics; 2 Next-Generation Sequencing; 2.1 Background; 2.2 NGS Workflow; 2.2.1 Library Generation; 2.2.2 Sequencing; 2.2.3 Data Analysis; Mapping or Assembling Short Reads to a Reference Genome; De Novo Assembly of Short Reads
,
Visualizing and Annotating the Mapped or Assembled Results
Additional Edition:
ISBN 9788132211839
Additional Edition:
Druckausg. ISBN 978-813-2211-83-9
Language:
English
Keywords:
Individualisierte Medizin
;
Genanalyse
;
Pharmakogenetik
DOI:
10.1007/978-81-322-1184-6
Bookmarklink